Indonesia Commits $1 Million to Global Vaccine Initiative

Strategic Insights -

As the world continues to grapple with the COVID-19 pandemic, Indonesia has made a significant commitment to support global efforts to develop vaccines for various diseases that could lead to pandemics. The country has pledged $1 million to the Coalition for Epidemic Preparedness Innovations (CEPI), a Oslo-based organization that aims to develop vaccines for emerging diseases.

The announcement was made during a virtual signing of a bilateral contribution agreement between Indonesian Foreign Minister Retno Marsudi and CEPI officials. Marsudi emphasized the importance of vaccine multilateralism in protecting people and the world from pandemics, and reiterated Indonesia's commitment to ensuring fair, affordable, and equitable access to vaccines for all countries.

CEPI CEO Richard J. Hatchett welcomed Indonesia's membership and emphasized the need for a global effort to develop and distribute vaccines. He noted that while two COVID-19 vaccine candidates had reported positive outcomes in clinical trials, the challenge lies in manufacturing and delivering the vaccines on a global scale.

Indonesia's contribution comes as the country is also boosting its production capacity to produce up to 250 million doses of COVID-19 vaccines next year. State-owned vaccine manufacturer Bio Farma is partnering with Chinese companies Sinovac and Sinopharm to develop the vaccines, which are undergoing clinical trials in Indonesia.

Key Takeaways:

  • Indonesia has committed $1 million to the Coalition for Epidemic Preparedness Innovations (CEPI) to develop vaccines for diseases that could lead to pandemics.
  • The country's Foreign Minister, Retno Marsudi, emphasized the importance of vaccine multilateralism and ensuring fair, affordable, and equitable access to vaccines for all countries.
  • CEPI CEO Richard J. Hatchett noted that while two COVID-19 vaccine candidates have reported positive outcomes in clinical trials, the challenge lies in manufacturing and delivering the vaccines on a global scale.
  • Indonesia's state-owned vaccine manufacturer Bio Farma is boosting its production capacity to produce up to 250 million doses of COVID-19 vaccines next year.
  • The country is partnering with Chinese companies Sinovac and Sinopharm to develop the vaccines, which are undergoing clinical trials in Indonesia.

Statistics:

  • $1 million: Indonesia's contribution to the Coalition for Epidemic Preparedness Innovations (CEPI)
  • 250 million doses: Bio Farma's target production capacity for COVID-19 vaccines next year
  • 2: The number of COVID-19 vaccine candidates that have reported positive outcomes in clinical trials
  • 48: The total number of COVID-19 vaccine candidates globally
  • 8: The number of COVID-19 vaccine candidates that have entered clinical trials globally
  • 9: The number of COVID-19 vaccine candidates that CEPI has invested in

Sources:

  • Arab News, "Indonesia commits $1 million to global vaccine initiative" (no date)
  • CEPI, "Indonesia joins CEPI to support global vaccine development" (no date)
  • Bio Farma, "Bio Farma to produce 250 million doses of COVID-19 vaccine next year" (no date)
  • Indonesian Ministry of Trade, "Indonesia's G20 Action Plan in response to COVID-19 pandemic" (no date)
  • Indonesian Ministry of Health, "Indonesia's COVID-19 vaccination plan" (no date)